RVL Pharmaceuticals
Nicole Price is an experienced professional in the pharmaceutical and healthcare sectors, currently serving as the Ophthalmic & Aesthetics Business Development Manager at RVL Pharmaceuticals, Inc. since April 2021. Nicole successfully launched the first FDA-approved prescription eyedrop for acquired blepharoptosis treatment, with expertise in engaging various medical professionals including ophthalmologists and plastic surgeons. Previously, as a Cardiovascular Sales Representative at Amarin Corporation, Nicole played a key role in the launch of Vascepa’s FDA-approved indication for P-CVR, targeting cardiologists and primary care physicians. Earlier experience includes serving as a Provider Engagement Coordinator at Advantasure, focusing on medical practice documentation improvement, and as a Clinical Allergy Specialist at United Allergy Services, enhancing the effectiveness of immunotherapy processes. Nicole holds a Bachelor of Science in Health Services Administration from Ohio University.
This person is not in any offices
RVL Pharmaceuticals
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.